Benzinga | Jan 19, 2022 08:20AM EST

Maxim Group Initiates Coverage On Kiora Pharmaceuticals with Buy Rating, Announces Price Target of $2.5

Maxim Group analyst Jason McCarthy initiates coverage on Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy rating and announces Price Target of $2.5.